血清S100β蛋白及NSE联合检测在手足口病脑损伤诊断中的临床价值

摘要

Objective To study the clinical application value of S100βserum protein and serum neu-ron-specific enolase (NSE) joint detection in the diagnosis of children with hand-foot-and-mouth disease (HFMD) combine brain injuries. Methods 318 cases of children with HFMD from October 2014 to February 2015 in our hospital were collected, and they were divided into mild group (157 cases), severe group (104 cases) and critical illness group (57 cases) according to the clinical manifestations. 100 cases of healthy chil-dren were selected as the control group. The S100βprotein and NSE levels of all the children were detected , and the results were analyzed statistically. Results There were statistical significance in the differences of S100βprotein and NSE levels among HFMD each groups and control group (F=7.91, F=6.37, Pall=0.010). The S100βprotein and NSE levels in HFMD each groups were all higher than that of control group , and the differences all had statistical significance(Pall<0.05). The S100βprotein and NSE levels increased along with the severity of patient's condition, and the differences all had statistical significance between each two HFMD groups (Pall<0.05). The S100βprotein and NSE levels of severe group in post treatment were all lower than that of before treatment, and the differences all had statistical significance (t=12.35, t=9.71, Pall<0.05). There were no statistical significance in the differences of S100βprotein and NSE levels of critical illness group between before and post treatment(t=0.23, t=0.21, Pall>0.05). Conclusion The detection of serum S100βprotein and NSE can be used for the early diagnosis, condition judgment, and the evaluation of treatment effect and prognosis of HFMD combine brain injuries.%目的：探讨S100β蛋白及神经元特异性烯醇化酶（neuron-specific enolase， NSE）联合检测在手足口病（hand-foot-and-mouth disease， HFMD）诊疗中的临床应用价值。方法收集2014年10月至2015年2月我院收治的318例HFMD患儿，根据临床表现分为轻症组157例、重症组104例、危重症组57例，同期选择100例健康体检儿童为健康对照组，检测受试儿童血清S100β蛋白及NSE水平，重症组及危重症组患儿于治疗1w后复检，对检测结果进行统计学分析。结果健康对照组及HFMD各组间血清S100β蛋白及NSE检测结果差异均有统计学意义（F＝7.91，F＝6.37，P均＝0.010）。HFMD各组血清S100β蛋白及NSE检测结果均高于健康对照组，且差异均有统计学意义（P均＜0.05）；且随着病情严重程度的增加，血清S100β蛋白及NSE检测结果均逐渐升高，各组间两两比较，差异均有统计学意义（P均＜0.05）。重症组HFMD患儿治疗后血清S100β蛋白及NSE检测结果均低于治疗前，且差异均有统计学意义（t＝12.35，t＝9.71，P均＜0.05）；危重症组HFMD患儿治疗前后血清S100β蛋白及NSE检测结果差异均无统计学意义（t＝0.23，t＝0.21，P均＞0.05）。结论血清S100β蛋白及NSE水平的检测可用于HFMD患儿合并脑损伤的早期诊断、病情判断、治疗效果及预后评估。